

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|--|--|--|-------------------------------|-----------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/560953 |
| | | | | Filing Date | 6/16/2004 |
| Date Submitted: November 17, 2010 (use as many sheets as necessary) | | | | First Named Inventor | Beverly L. Wolgast |
| | | | | Art Unit | 1624 |
| Sheet 1 of 2 | | | | Examiner Name | COLEMAN, BRENDA LIBBY |
| | | | | Attorney Docket Number | 098817-0642 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|--|
| | A44 | 3,652,543 | 03-28-1972 | Hoegerle, Karl | |
| | A45 | 60/479,280 | N/A | Smith, et al. | |
| | A46 | 60/512,967 | N/A | Burbaum et al. | |
| | A47 | 60/789,191 | N/A | Arena Pharmaceutical | |
| | A48 | 61/268,930 | N/A | Arena Pharmaceutical | |
| | A49 | 12/517,625 | N/A | Gharbaoui et al. | |
| | A50 | 2010/0173894 | 07-08-2010 | Smith, et al. | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Application Document Serial Number-Kind Code ² (if known) | Filing Date of Cited Document MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--|--|--|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Documents | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|---|--|----------------|
| | B73 | CH500194 | 12-15-1970 | CIBA GEIGY AG [CH] | | |
| | B74 | JP 62-267250 | 11-19-1987 | PFIZER LTD. | | |
| | B75 | JP 2000-44533 | 02-15-2000 | Mita Shirou, et al. | | |
| | B76 | JP 2-502723 | 08-30-1990 | SCHERING PLOUGH CORP | | |
| | B77 | JP 2001-89472 | 04-03-2001 | HOFFMANN LA ROCHE | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|-----------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2010 (use as many sheets as necessary) | | Application Number | 10/560953 |
| | | Filing Date | 6/16/2004 |
| | | First Named Inventor | Beverly L. Wolgast |
| | | Art Unit | 1624 |
| | | Examiner Name | COLEMAN, BRENDA LIBBY |
| | | Attorney Docket Number | 098817-0642 |
| Sheet | 2 | of | 2 |

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | C109 | CASY, et al., "Some Arylalkylamino Analogs Of Acyclic Analgetics", <i>J Med Chem.</i> , (1968) ,11(3):599-601 | |
| | C110 | CHANG, et al., "Dopamine Receptor Binding Properties of Some 2,3,4,5-Tetrahydro-1H-3-Benzazepine-7-ols With Non-Aromatic Substituents In The 5-Position", <i>Bioorganic & Med. Chem. Letters</i> , (1992) 2(5):399-402 | |
| | C111 | LADD, et al., "Synthesis and Dopaminergic Binding of 2-Aryldopamine Analogues: Phenethylamines, 3-Benzazepines, and 9-(Aminomethyl)fluorenes", <i>J. Med. Chem.</i> , (1986) 29(10):1904-1912 | |
| | C112 | TIETZE, et al., "Efficient Synthesis of 2,3,4,5-Tetrahydro-1H-3-benzazepines by Intramolecular Heck Reaction", <i>J. of Synthetic Organic Chem.</i> , (1993) pp. 876-880, Thieme Stuttgart, New York | |
| | C113 | U.S. Application Serial No. 11/599,050 - Final Office Action dated August 20, 2010 | |
| | C114 | U.S. Application Serial No. 11/793,941- Non-final Office Action (Restriction Requirement) dated September 17, 2010 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.